Search Medical Condition
Please enter condition
Please choose location
 

Imperial, California Clinical Trials

A listing of Imperial, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (19) clinical trials

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD)

Investigation of the efficacy and safety of a new potential treatment of Major depressive disorder (MDD) in paediatric patients (age 7 to 11 years)

Phase

0.0 miles

Learn More »

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) diagnosis of Major depressive disorder (MDD).

Phase

0.0 miles

Learn More »

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)

This study will evaluate the efficacy, safety, and tolerability of rapastinel 450 milligrams (mg) compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to ADT.

Phase

0.21 miles

Learn More »

A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder

This study will evaluate the efficacy, safety and tolerability of rapastinel 450 milligrams (mg) intravenous (IV) once weekly or once every 2 weeks versus placebo as an adjunctive treatment to ongoing anti-depressive therapy (ADT) in the prevention of relapse in participants with Major Depressive Disorder (MDD).

Phase

0.21 miles

Learn More »

Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder

This study will evaluate the long-term safety and tolerability of rapastinel as an adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD).

Phase

0.21 miles

Learn More »

Has your child been diagnosed with depression? Has your child been struggling with feelings of depression? You may be interested in learning more about the Engage clinical research studies for children and adolescents with major depressive disorder (MDD). About the Engage Clinical Research Studies The Engage clinical research studies are ...

Phase N/A

0.21 miles

Learn More »

Efficacy Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.

Phase

0.21 miles

Learn More »

Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder

Study LVM-MD-11 is a randomized, double-blind, placebo- and active-controlled, parallel group, fixed-dose study in adolescent patients, ages 12-17 years. The study will be approximately 10 weeks in duration: - 1-week screening/washout period - 8-week double-blind treatment period - 1-week double-blind down-taper period Patients who meet the eligibility criteria at Visit ...

Phase

0.21 miles

Learn More »

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)

The purpose of this study is to demonstrate the efficacy, safety and tolerability of SPN-810 in the treatment of impulsive aggression in patients with Attention Deficit/Hyperactivity Disorder (ADHD) in conjunction with standard ADHD treatment. Approximately 291 subjects aged 6 to 12 years with ADHD and comorbid impulsive aggression will be ...

Phase

0.21 miles

Learn More »

Study for Pediatric ADHD Learning that your [4 to 12] [4 or 5] year old child has attention-deficit/hyperactivity disorder (ADHD) is challenging. It may leave you wondering what options are available for your child and whether they will be safe for your child at such a young age. New clinical ...

Phase N/A

0.21 miles

Learn More »